Mpact 3D Metal Monolit Study

Prospective, Multicentre, Non-randomised, Open Study Evaluating the Efficacy and Fixation of the Mpact 3D Metal Monolit Cup

Total hip arthroplasty (THA) is one of the most common operations performed in orthopaedics to improve a patient's quality of life.

Surgeons are constantly seeking to improve all aspects of care related to this procedure, whether it be improving implant technology, improving instrumentation or the technique involved in performing the procedure.

In recent years, a new porous titanium coating has been introduced to promote good osseointegration of uncemented cups. High friction torque and a feeling of immediate anchorage provide excellent primary stability, while high porosity ensures bone growth providing secondary stability. With higher porosity than standard coatings, a greater volume of bone can be present in the porous surface, giving a proportional increase in force at the interface. he Mpact 3D Metal Monolith cup has been designed to provide greater range of motion and improved joint stability, with a reduced risk of dislocation. It is an innovative design that improves stability and provides a favourable environment for long-term biological metal-bone fixation.

The current study aims to collect clinical and radiological data to assess the function of the operated hip and the stability of the Mpact 3D Metal Monolith cup at 2 years and survival at 5 years for the treatment of patients requiring hip arthroplasty.

Study Overview

• Status: Recruiting
• Conditions: Total Hip Arthroplasty (THA)
• Intervention / Treatment: Device: Mpact 3D Metal Monolith

• Study Type: Observational
• Enrollment (Estimated): 88

Contacts and Locations

• Study Contact: Name: Philippe Anract; Phone Number: 01 58 41 30 38; Email: philippe.anract@aphp.fr

Study Locations

• France
  • Nantes, France, 44000
    • Not yet recruiting
    • Clinique Brétéché
    • Contact: Kamel Ajouy; Phone Number: 02 51 86 78 50; Email: kamajouy@yahoo.fr
  • Paris, France, 75014
    • Recruiting
    • Hopital Cochin
    • Contact: Philippe Anract; Phone Number: 01 58 41 30 38; Email: philippe.anract@aphp.fr
  • Paris, France, 75010
    • Not yet recruiting
    • Hopital Lariboisière
    • Contact: Pascal Bizot; Phone Number: 01 49 95 91 38; Email: pascal.bizot@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients who meet the inclusion criteria

Description

Inclusion Criteria:

1. Patient with a disease that corresponds to the indications for use of Medacta implants (according to the instructions for use)
2. Patient eligible for primary total hip arthroplasty
3. Patient aged between 18 and 75 years
4. Patient covered by the French Social Security system or an equivalent protection scheme.
5. Patient able, in the investigator's opinion, to comply with the requirements of the study.

Exclusion Criteria:

1. Patient suffering from inflammatory arthritis
2. Previously operated hip
3. Patient requiring a transplant
4. Hip tumour involved
5. Patient with progressive local or systemic infection
6. Severe acetabular dysplasia
7. Patient with muscle loss, neuromuscular disease or vascular impairment of the affected limb.

4. Patient with known medical problems that may compromise independent recovery of mobility 5. Patient with a BMI greater than 40 kg/m². 6. Patient with major cognitive impairment that prevents him/her from fully understanding the requirements of the study 7. Patient living in a geographical area where study follow-up is not possible. 8. Patient taking part in interventional research 9. Minor patient 10. Protected adult patient 11. Vulnerable person according to article L1121-6 of the Public Health Code

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the hip function	The Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and is intended to evaluate various hip disabilities and methods of treatment in an adult population. The original version was published 1969[1]. The HHS is an outcome measure administered by a qualified health care professional, such as a physician or a physical therapist. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. Results can be recorded and calculated online. The maximum score possible is 100. Results can be interpreted with the following: <70 = poor result; 70-80 = fair, 80-90 = good, and 90-100 = excellent.	Preoperative, 3 months, 6 months, 1 year, 2 years, 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Analysis of the primary stability of the implant at 2 years	Protocol EBRA-Cup: Measurement of longitudinal/transversal migration of acetabular cup in digital serial radiographs (minimum of 4 x-rays per series). Full size AP pelvis radiographs are required. Accuracy: +/- 1mm.	2 years
Analysis of the wear of the polyethylene insert (HighCross) at 2 years	Martell method of linear wear measurement	2 years
Evaluation of the fixation and osteolysis	Radiological analysis	Immediate postoperative, 3 months, 6 months, 1 year, 2 years, 5 years
Evaluation of the mobility	The Oxford Hip Score (OHS) is a joint-specific, patient-reported outcome measure designed to assess disability in patients undergoing total hip replacement. The OHS is a short 12-item survey that can be done with pen and paper. Patients are asked to reflect on their pain and functional ability over the previous four weeks. There are two domains (pain and function) with six items or questions in each. Each item has five possible responses. In the original scoring responses were from 1 = least difficult to 5= most difficult. Item scores are summed to give a total score from anywhere between 12 and 60. The lower the score, the better the outcome.	Preoperative, 3 months, 6 months, 1 year, 2 years, 5 years
Evaluation of the safety of the implant	Collection of intraoperative and postoperative complications	Intraoperative, immediate postoperative, 3 months, 6 months, 1 year, 2 years, 5 years
Evaluation of the survival of the implant	Kaplan-Meier survival method	3 months, 6 months, 1 year, 2 years, 5 years

Collaborators and Investigators

• Sponsor: Medacta International SA

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2024
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: December 16, 2024
• First Submitted That Met QC Criteria: December 23, 2024
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 23, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: P01.028.01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No